Juliet Hull Elected Non-Executive Director

NZX Announcement

11 September 2020

JULIET HULL ELECTED NON-EXECUTIVE DIRECTOR
Truscreen Group Limited (NZX:TRU) (Truscreen or Company) is pleased to confirm the election of Ms Juliet
Hull as a non-executive director of Truscreen at yesterday’s meeting of shareholders.
Ms Hull is the NZ General Manager/Country Director of Johnson & Johnson Medical (J & J), a director of the
ANZ Johnson & Johnson Medical Executive Board, a director of MTANZ (Medical Technology Association of
NZ) and a member of both the APAC Regional Leadership team for J & J’s Orthopaedics and Ethicon Divisions.
Ms Hull is a senior executive with more than 20 years’ experience in Asia Pacific markets in Healthcare sales,
marketing and leadership.
Ms Hull holds a Master of Business and Administration (Macquarie Graduate School of Management, Sydney,
Australia) and Bachelor of Nursing (Auckland University of Technology), Auckland, New Zealand).
Tony Ho, Chairman commented “ we are delighted to welcome Ms Juliet Hull to the Board of Truscreen. Her
enthusiasm and healthcare expertise in the Asia Pacific region will be invaluable to the Company.”
Mr Con Hickey, retired from the Board at yesterday’s Annual Meeting. The board thanks Mr Con Hickey for
his significant contribution to the Company.

-ENDS-
For more information, visit

www.truscreen.com or contact:

Anthony Ho
Chairman
tonyho@truscreen.com

About TruScreen:
TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-
time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-
being of women around the world.
TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the
cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.
TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with
conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for
supporting laboratory infrastructure. As such, TruScreen’s target market is low and middle-income countries
where no large-scale cervical cancer screening programs and infrastructure are in place, such as China,
Mexico, Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for
use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is
significant.